newsfilter
← Latest News
Business Wire·

Precision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Study

- Arkansas Children's Hospital activated as the first clinical trial site and now enrolling patients in the FUNCTION-DMD study of PBGENE-DMD - Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing